The FDA exclusivity for Plavix (clopidogrel) ended on May 17, 2012, while patent protection expires January 31, 2014. This exciting news brings Clopidogrel CAS# 113665-84-2, to the forefront of pharmaceutical news. With sales of Plavix generating billions of dollars for Bristol-Myers Squibb/Sanofi Pharmaceuticals, researchers are clamoring to create generic options of clopidogrel. As an antiplatelet[…]
Patients With Stents Benefit From Clopidogrel
Antithrombotic, Blood Product, Bulk Active Ingredient, Drug Research & Development API, Patent Expiration 2012, Patent Expiration 2014, TEVA API Tags: atrial fibrillationPlavixWarfarin Jul 24, 2012
Sirolimus Continues to be Effective, Even When Thought to be Contraindicated
Drug Research & Development API, Immunosuppressant, Patent Expiration 2012, Patent Expiration 2013 Tags: hypertensionImmunosuppressantPfizerSirolimus May 21, 2012
As an immunosuppressant drug used to prevent transplant rejection, Sirolimus, CAS number 53123-88-9, is a macrolide. Particularly useful for kidney transplant patients, sirolimus is also known as the brand name Rapamune, which is marketed by Pfizer. The first patent for Rapamune is set to expire in October 2012. An addtional patent will expire in July[…]
